An oncologist’s perspective on measuring success in the clinic

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Even though cancer center and health system leaders know this deep down, most also find no way better to measure the success of programs and providers than the inscrutable Relative Value Unit, or RVU.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Steven R. Grossman, MD, PhD
Professor of medicine, cancer physician in chief, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine of USC
Table of Contents

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more
Steven R. Grossman, MD, PhD
Professor of medicine, cancer physician in chief, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine of USC

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login